サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：骨肉腫診断と治療の世界市場（2022年～2028年）
市場調査レポート
商品コード
1123113

骨肉腫診断と治療の世界市場（2022年～2028年）

Global Bone Cancer Diagnosis and Therapeutics Market Research and Forecast 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 136 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
骨肉腫診断と治療の世界市場（2022年～2028年）
出版日: 2022年07月22日
発行: Orion Market Research
ページ情報: 英文 136 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の骨肉腫診断と治療の市場規模は、予測期間中に8.1%の大幅なCAGRで成長すると予測されています。パジェット病に関連する患者数の増加は、市場に影響を与え、市場を牽引する主要な要因の一つとなっています。また、一人当たりの医療費の増加、幹細胞移植の技術なども、市場の成長に大きく寄与している主要な要因であると予想されています。また、研究開発や技術の進歩は、市場に機会を生み出す要因の一部と考えられています。

当レポートでは、世界の骨肉腫診断と治療市場について調査分析し、市場概要、セグメント別の市場分析、競合情勢、主要企業などの情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と考察

  • 調査範囲
  • アナリストの考察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の発展
  • 主要戦略分析
  • COVID-19の主要企業への影響

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界の骨肉腫診断と治療市場：タイプ別
    • 原発性骨肉腫
    • 二次性骨肉腫
  • 世界の骨肉腫診断と治療市場：診断別
    • MRIスキャン
    • X線
    • CTスキャン
    • 放射性核種骨センサー
    • 生検
    • その他
  • 世界の骨肉腫診断と治療市場：治療法別
    • 放射線治療
    • 凍結手術
    • その他
  • 世界の骨肉腫診断と治療市場：エンドユーザー別
    • 総合病院
    • がん研究センター

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • その他の地域

第7章 企業プロファイル

  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • BeiGene
  • Eli lilly and company
  • F. Hoffmann-la roche ltd.
  • Infinity Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips N.V.
  • Merck & Co., Inc.
  • Merrion pharmaceuticals plc.
  • Novartis AG
  • Pfizer Inc.
図表

LIST OF TABLES

  • 1. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY TYPE,2020-2027($ MILLION)
  • 3. GLOBAL PRIMARY BONE CANCER MARKET BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL SECONDARY BONE CANCER MARKET BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY DIAGNOSIS,2020-2027 ($ MILLION)
  • 6. GLOBAL MRI SCAN MARKET BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL X-RAYS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL CT-SCAN MARKET BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL RADIONUCLIDE BONES SENSORS MARKET BY REGION, 2020-2027($ MILLION)
  • 10. GLOBAL BIOPSY MARKET BY REGION, 2020-2027($ MILLION)
  • 11. GLOBAL OTHER MARKET BY REGION, 2020-2027($ MILLION)
  • 12. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY THERAPIES, 2020-2027($ MILLION)
  • 13. GLOBAL RADIATION THERAPY MARKET BY REGION, 2020-2027($ MILLION)
  • 14. GLOBAL CRYOSURGERY MARKET BY REGION, 2020-2027($ MILLION)
  • 15. GLOBAL OTHER MARKET BY REGION, 2020-2027($ MILLION)
  • 16. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY END USER,2020-2027($ MILLION)
  • 17. GLOBAL MULTISPECIALTY HOSPITALS MARKET BY REGION, 2020-2027($ MILLION)
  • 18. GLOBAL CANCER RESEARCH INSTITUTE MARKET BY REGION, 2020-2027($ MILLION)
  • 19. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY GEOGRAPHY, 2020-2027($ MILLION)
  • 20. NORTH AMERICAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

21. NORTH AMERICAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027($MILLION)

22. NORTH AMERICAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027($MILLION)

23. NORTH AMERICAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027($MILLION)

24. NORTH AMERICAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END USER,2020-2027($MILLION)

25. EUROPEAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY,2020-2027 ($MILLION)

26. EUROPEAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027($MILLION)

27. EUROPEAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027($MILLION)

28. EUROPEAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027 ($MILLION)

29. EUROPEAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END USER,2020-2027($MILLION)

30. ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY,2020-2027 ($MILLION)

31. ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027($MILLION)

32. ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027($MILLION)

33. ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027($MILLION)

34. ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END USER,2020-2027($MILLION)

35. REST OF THE WORLD BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027($MILLION)

36. REST OF THE WORLD BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027($MILLION)

37. REST OF THE WORLD BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027($MILLION)

38. REST OF THE WORLD BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END USER,2020-2027($MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET, 2021-2027 (%)
  • 4. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 6. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS SHARE BY THERAPIES, 2020 VS 2027 (%)
  • 7. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS SHARE BY END USER, 2020 VS 2027 (%)
  • 8. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL PRIMARY BONE CANCER MARKET BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL SECONDARY BONE CANCER MARKET BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL MRI SCAN MARKET BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL X-RAYS MARKET BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL CT-SCAN MARKET BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL RADIONUCLIDE BONES SENSORS MARKET BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL BIOPSY MARKET BY REGION, 2020 VS 2027 (%)
  • 16. GLOBAL OTHER MARKET BY REGION, 2020 VS 2027 (%)
  • 17. GLOBAL RADIATION THERAPY MARKET BY REGION, 2020 VS 2027 (%)
  • 18. GLOBAL CRYOSURGERY MARKET BY REGION, 2020 VS 2027 (%)
  • 19. GLOBAL OTHER MARKET BY REGION, 2020 VS 2027 (%)
  • 20. GLOBAL MULTISPECIALTY HOSPITALS MARKET BY REGION, 2020 VS 2027 (%)
  • 21. GLOBAL CANCER RESEARCH INSTITUTE MARKET BY REGION, 2020 VS 2027 (%)
  • 22. US BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. CANADA BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. UK BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. FRANCE BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. GERMANY BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. ITALY BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. SPAIN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. REST OF EUROPE BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. INDIA BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. CHINA BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. JAPAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. SOUTH KOREA BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE,2020-2027 ($ MILLION)
  • 34. REST OF ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 35. REST OF THE WORLD BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
目次
Product Code: OMR2017198

Global Bone Cancer Diagnosis and Therapeutics Market Research By Type (Primary Bone Cancer and Secondary Bone Cancer), By Diagnosis (MRI Scans, X-Rays, CT-Scan, Radionuclide Bone Sensors, Biopsy and Other), By Therapies (Radiation Therapy, Cryosurgery and Other) and By End-User (Multispecialty Hospitals and Cancer Research Centers) Forecast 2021-2027

The global bone cancer diagnosis and therapeutics market is growing at a considerable CAGR of 8.1% during the forecast period. Rising number of incidences in individual related to Paget disease is one of the prime factors affecting and driving the market. Increasing per capita healthcare expenditure, technology for stem cell transplants among others is also estimated to be the key factors that are contributing significantly towards the growth of the market. However, lack of awareness in under developed nations with regards to diagnosis and therapeutics along with high cost involvement in treatment are some major factors constraints that are hindering the growth of the global bone cancer diagnosis and therapeutics market.

However, R&D and technological advancement are some of the key factors that are creating opportunities for the market. New product launches in the market are likely to drive the growth of the global bone cancer diagnosis and therapeutics market. For instance, in November 2020, BeiGene had officially notified the approval in China for its XGEVA (denosumab). This approval was received in China for the patients suffering due to bone metastasis from solid tumors along with patients having multiple myeloma in order to prevent skeletal-related events.

Impact of COVID-19 on the Global Bone Cancer Diagnosis and Therapeutics Market

The global bone cancer diagnosis and therapeutics market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted manufacturing and transportation activities. Moreover, the operations and procedures related to surgery were also interrupted due to the COVID-19 pandemic that had adversely impacted the market.

Segmental Outlook

The market is segmented based on type, diagnosis, therapies and end-user. Based on by type, market is segmented into primary bone cancer and secondary bone cancer. By diagnosis, market is segmented into MRI scans, x-rays, CT-scan, radionuclide bone sensors, biopsy and other. Further by therapies the market is segmented into radiation therapy, cryosurgery and other. By end user the market is segmented into multispecialty hospitals and cancer research centers.

Global Bone Cancer Diagnosis and Therapeutics Market by Type 2020 (%)

Global Bone Cancer Diagnosis and Therapeutics Market by Type

Based on the type, primary bone cancer holds significant share in the market. It is a type of cancer that occurs and begins in the bone. It may occur to the patient on the surface, in the outer layer or it can be observed from the center of the bone. The treatment is very necessary if it is left untreated it can spread to other body parts. Further, According to Australian institute of health and wealth around 250 Australians every year are been diagnosed with primary bone cancer. More than 30 types of bone cancer are considered in this category; however most commonly observed includes Osteosarcoma, Chondrosarcoma and Ewing's sarcoma. This can be treated through surgery and various type of therapy given to patients.

Regional Outlooks

The global bone cancer diagnosis and therapeutics market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global bone cancer diagnosis and therapeutics market. Some factors that are boosting the market growth in North America are high expenditure in healthcare along with increasing prevalence of bone cancer. Additionally, development in technology and research projects conducted in the region is other factor to driving the growth of the market. For instance, In February 2020, one of the organizations catalyzing research initiatives named as Count Me In has set forth the launch of the project that name as osteosarcoma project. This project is considered as patient -partnered effort that supports accelerating research work for people in countries that include the US and Canada those who have been affected by osteosarcoma.

Global Bone Cancer Diagnosis and Therapeutics Market, by Region 2021-2027

Global Bone Cancer Diagnosis and Therapeutics Market, by Region

Asia-Pacific will have Considerable Growth in the Global Bone Cancer Diagnosis and Therapeutics Market

Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing number of cancer patients along with growing geriatric population is likely to drive the growth of the regional market. Further, due to health availability, rising health care expenditure along with rising number of market player in India, China and South Korea are also some of the factors that are affecting and impacting the growth.

Market Player Outlook

Key players of the global bone cancer diagnosis and therapeutics market are Amgen Inc., Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others. To survive in the market, these players adopt different marketing strategies such as product launches and acquisition. For instance, in October 2020, Johnson & Johnson Services, had notified its acquisition of momenta pharmaceuticals, Inc. which is one of the companies that offers therapies. The acquisition was done for around $6.5 billion as this would play an important role for providing their assistance in advance patient care.

In September 2020, Bristol-Myers Squibb Co. had announced that the company has received approval and clearance from heath Canada for INREBIC. This would support in treating patients by offering them once in a day oral option who had been affected by rare bone marrow cancer. These new treatments would be helpful in effectively treating rare disorders.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global bone cancer diagnosis and therapeutics market based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Bone Cancer Diagnosis and Therapeutics Industry
  • Recovery Scenario of Global Bone Cancer Diagnosis and Therapeutics Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Bone Cancer Diagnosis and Therapeutics Market by Type
    • 5.1.1. Primary Bone Cancer
    • 5.1.2. Secondary Bone Cancer
  • 5.2. Global Bone Cancer Diagnosis and Therapeutics Market by Diagnosis
    • 5.2.1. MRI Scans
    • 5.2.2. X-Rays
    • 5.2.3. CT-Scan
    • 5.2.4. Radionuclide Bone Sensors
    • 5.2.5. Biopsy
    • 5.2.6. Other
  • 5.3. Global Bone Cancer Diagnosis and Therapeutics Market by Therapies
    • 5.3.1. Radiation Therapy
    • 5.3.2. Cryosurgery
    • 5.3.3. Other
  • 5.4. Global Bone Cancer Diagnosis and Therapeutics Market by End User
    • 5.4.1. Multispecialty Hospitals
    • 5.4.2. Cancer Research Centers

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Amgen Inc.
  • 7.2. Bayer AG
  • 7.3. Bristol-Myers Squibb Co.
  • 7.4. BeiGene
  • 7.5. Eli lilly and company
  • 7.6. F. Hoffmann-la roche ltd.
  • 7.7. Infinity Pharmaceuticals, Inc.
  • 7.8. Johnson & Johnson Services, Inc.
  • 7.9. Koninklijke Philips N.V.,
  • 7.10. Merck & Co., Inc.
  • 7.11. Merrion pharmaceuticals plc.
  • 7.12. Novartis AG
  • 7.13. Pfizer Inc.